

**Amendment to the Claims:**

This listing of claims will replace all prior listings of claims in the application:

**Listing of Claims:**

1. (Currently Amended) An antineoplastic dendritic polymer conjugate,  
comprising:  
  
a dendritic polymer conjugated to an antineoplastic agent  
  
wherein the dendritic polymer is a poly(amidoamine)dendrimer having  
carboxylate functional groups,  
  
wherein the antineoplastic agent is cisplatin or carboplatin and is  
encapsulated within the dendritic polymer,  
  
wherein the percent by weight of platinum in the conjugate is [from  
15% to 25%] at least about 16%, and  
  
wherein the antineoplastic dendritic polymer conjugate has a  
therapeutic effect on malignant tumors.
2. (Cancelled)
3. (Cancelled)
4. (Cancelled)
5. (Cancelled)
6. (Cancelled)
7. (Cancelled)
8. (Cancelled)

9. (Cancelled)
10. (Cancelled)
11. (Cancelled)
12. (Previously Amended) The antineoplastic dendritic polymer conjugate of claim 1, wherein the dendritic polymer is acrylate derived.
13. (Previously Amended) The antineoplastic dendritic polymer conjugate of claim 12, wherein the conjugate is an aggregate of poly(amidoamine)-dendrimers of generation 3.5, ethylenediamine core, with cisplatin.
14. (Previously Amended) The antineoplastic dendritic polymer conjugate of claim 1, wherein the molar ratio of the cisplatin to dendritic polymer in the conjugate is from about 100:1 to about 1:1.
15. (Previously Amended) The antineoplastic dendritic polymer conjugate of claim 13 or 14, wherein the molar ratio of cisplatin to dendritic polymer in the conjugate is about 35:1.
16. (Cancelled)
17. (Cancelled)
18. (Cancelled)
19. (Previously Amended) The antineoplastic dendritic polymer conjugate of claim 1, wherein the antineoplastic agent is cisplatin.
20. (Previously Added) The antineoplastic dendritic polymer conjugate of claim 1, wherein the poly(amidoamine)dendrimer is a generation from 3.5 to 7.5.